PROVIDENCE - real-world study in patients with HER2-positive unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan and offered PRO-React Onco - PROVIDENCE

This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan in patients with Human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer, who were offered to use CANKADO PRO-React Onco, in Germany.

Eligible participants will be those diagnosed with HER2-positive, unresectable or metastatic breast cancer, who have received one prior HER2-targeted therapy and are now scheduled to receive T-DXd in second line. Further, all eligible participants are offered to use CANCADO PRO-React Onco, an in Germany approved and reimbursed digital healthcare application (DiGA) for assistance of patients with breast cancer and their oncologist during cancer treatment. All diagnostic and treatment procedures including visit frequency are at the discretion of the treating physician and not defined by the protocol. T-DXd treatment and DiGA are considered as a selection criteria. Approximately 390 eligible participants will be enrolled into 1 of 2 cohorts, according to the CANKADO PRO-React Onco user behavior.